Pathophysiology and management of the serotonin syndrome

Annals of Pharmacotherapy

Volumn 30, Issue 5, 1996, Pages 527-533

  Brown, Thomas M ^a   Skop, Brian P ^b   Mareth, Thomas R ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b Department of Psychiatry ^*

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN;

ABDOMINAL PAIN; CLINICAL FEATURE; DIAPHORESIS; DIARRHEA; DRUG METABOLISM; DYSPNEA; FEVER; HUMAN; HYPERREFLEXIA; HYPERTENSION; MYOCLONUS; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEROTONINERGIC SYSTEM; SHIVERING; SYNDROME; THROMBOCYTOPENIA; TREMOR;

EID: 0030010111     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000517     Document Type: Review

References (61)

1. Cruzon G, Ettlinger G, Cole M, Walsh J. The biochemical, behavioral, and neurologic effects of high L-tryptophan intake in the rhesus monkey. Neurology 1963;12:431-8.
2. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
3. Beasley CM, Masica DN, Heiligenstein JH, Wheadon DE, Zerbee RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
4. Hoyer D, Middlemiss AD. Species differences in the pharmacology of terminal autoreceptors in mammalian brain. Trends Pharmacol Sci 1989;10:130-2.
5. 1A auto receptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 1993;60:776-9.
6. Deakin JFW, Graeff FG, Guimares FS. Acute uptake inhibitors do not increase 5-HT availability (letter). Trends Pharmacol Sci 1993;14:398.
7. 1 receptors modulating transmitter release in rat cerebellum. J Pharmacol Exp Ther 1986;237:644-8.
8. 3-subunits with serotonergic and GABAergic neurons. Neuroscience 1993;54:881-92.
9. Maura G, Fedele E, Raiteri M. Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine. Eur J Pharmacol 1989;165:173-9.
10. 1A agonists 8-OH-DPAT and ipsapirone in vitro. Eur J Pharmacol 1990;175:145-53.
11. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604.
12. Skop BP, Brown TM, Potential bleeding and vascular complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996;37:12-6.
13. Gibbs DM. Hyperventilation-induced cerebral ischemia in panic disorder and effect of nimodipine. Am J Psychiatry 1991;149:1589-91.
14. 1-like receptors mediate 5-hydroxytryptamine-induced contraction of human basilar artery. Br J Pharmacol 1989;96:434-49.
15. Skop BP, Finkelstein J, Mareth TR, Magoon M, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease: a case report and review. Am J Emerg Med 1994;12:642-4.
16. Brown TM, Skop BP. Nitroglycerin in the treatment of the serotonin syndrome (letter). Ann Pharmacother 1996;30:191.
17. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995;152:122-5.
18. Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neuroscience 1993;16:346-52
19. Westheimer R, Klawans HL. The role of berotonin in the pathophysiology of myoclonus seizures associated with acute imipramine toxicity. Neurology 1974;24:1175-7.
20. Gimenez-Roldan S, Mateo D, Muradas V, De Yebens JG. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity. Clin Neuropharmacol 1988;11:151-60
21. Jacobs BL. Serotonin and behavior: emphasis on motor control. J Clin Psychiatry 1991;52(suppl 12): 17-23
22. Murphy DL, Lesch KP, Aulakh CS, Pigott TA. III. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 1991;43:527-52.
23. 2 receptor mediates serotonin-induced electrolyte transport in rat left colon. J Surg Res 1993;55:323-9.
24. Stewart CP, Turnberg LA. A microelectrode study for responses to secretogogues by epithelial cells on villus and crypt of rats' small intestine. Am J Physiol 1989;257:G334-9.
25. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992;66:198-203.
26. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin receptors. Neuroscience 1987;21:123-9.
27. 2 receptor-mediated pulmonary and vascular and airway smooth muscle contraction. Pulm Pharmacol 1988;1:93-9.
28. Gillis RA, Hill KJ, Kirby JS, Quest JA, Hamosh P, Norman WP, et al. Effect of activation of central nervous system serotonin 1A receptors on cardiorespiratory function. J Pharmacol Exp Ther 1989;248:851-7.
29. McCall RE, Patel BN, Harris LT. Effects of serotonin, and serotonin 2 receptor agonists and antagonists on blood pressure, heart rate, and sympathetic nerve activity. J Pharmacol Exp Ther 1987;242:1152-9
30. Vogel RA. Endothelium-dependent vasoregulation of coronary diameter and blood flow. Circulation 1993;88:325-7.
31. Ortiza J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol 1992;105:941-6.
32. Lefebrve H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol 1995;42:95-8.
33. Tyce GM Origin and metabolism of serotonin J Cardiovasc Pharmacol 1990;16(suppl 3):51-7.
34. Celda P, Artigas F. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues. J Neurochem 1993;59:2191-8.
35. Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch Gen Psychiatry 1994;51:34-8.
36. Van Kempen GMJ, Notten P, Hengeveld MW. Repeated measures of platelet MAO activity and 5-HT in a group of suicidal women. Biol Psychiatry 1992;31:529-30.
37. Dunn AJ, Welch J. Stress- and endotoxin-induced increases in brain tryptophan and serotonin metabolism depend upon sympathetic nervous system activity. J Neurochem 1991;57:1615-22.
38. Hourani SMO, Cusack NJ. Pharmacological receptors on blood platelets. Pharmacol Rev 1991;43:243-98.
39. Bradbury AJ, Costall B, Naylor RJ, Onaivi ES. 5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse Psychopharmacology 1987;93:457-65.
40. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G. Am phetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters Mol Pharmacol 1993;44:1227-31.
41. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the rat raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992;25:243-50.
42. Kreiss DS, Wieland S, Lucki I. The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release. Neuroscience 1993;52:295-301.
43. 14C] 5-hydroxytryptamine from human platelets by red wine. Life Sci 1991;48:2297-300.
44. Pattichis K, Louca LL, Jarman J, Sandler M, Glover V. Phenolic substances in red wine and release of platelet 5-hydroxytryptamine (letter). Lancet 1993;341:1104.
45. Bostwick JM, Brown TM. Ruoxetine and phentermine interaction may produce the serotonin syndrome. J Clin Psychopharmacol (in press).
46. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(suppl A):34-9.
47. Gaddum JH, Picarelli ZP. Two types, of tryplamine receptor (letter). Br J Pharmacol 1957;12:323.
48. 3 receptor agents. Pharmacol Rev 1991;43:579-86.
49. 4 receptors: potential therapeutic implications in neurology and psychiatry. Cent Nerv Syst Drugs 1994;1:6-15.
50. B receptors to the same channels in hippocampus. Science 1986;234:1261-5.
51. Gavish M, Katz Y, Bar-Ami S, Weizman R. Biochemical, physiologic al, and pathological aspects of the peripheral benzodiazepine receptor. J Neurochem 1992;58:1589-1601.
52. Lauterbach EC. Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia. Clin Neuropharmacol 1991;14:547-55.
53. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-8.
54. Weizman R, Gavish M. Molecular, cellular and behavioral aspects of peripheral-type benzodiazepine receptors. Clin Neuropharmacol 1993;16:401-17.
55. 3 antagonists: preclinical data. In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven Press, Ltd, 1992:211-23.
56. DeVanme CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55(suppl 12):38-45.
57. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet 1995;29(suppl 1):33-44.
58. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-14.
59. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
60. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
61. Guze BH, Baxter LR. The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol 1986;6:119-20.